Literature DB >> 18245231

Capacity of human nisin- and pediocin-producing lactic Acid bacteria to reduce intestinal colonization by vancomycin-resistant enterococci.

Mathieu Millette1, Gilbert Cornut, Claude Dupont, François Shareck, Denis Archambault, Monique Lacroix.   

Abstract

This study demonstrated the capacity of bacteriocin-producing lactic acid bacteria (LAB) to reduce intestinal colonization by vancomycin-resistant enterococci (VRE) in a mouse model. Lactococcus lactis MM19 and Pediococcus acidilactici MM33 are bacteriocin producers isolated from human feces. The bacteriocin secreted by P. acidilactici is identical to pediocin PA-1/AcH, while PCR analysis demonstrated that L. lactis harbors the nisin Z gene. LAB were acid and bile tolerant when assayed under simulated gastrointestinal conditions. A well diffusion assay using supernatants from LAB demonstrated strong activity against a clinical isolate of VRE. A first in vivo study was done using C57BL/6 mice that received daily intragastric doses of L. lactis MM19, P. acidilactici MM33, P. acidilactici MM33A (a pediocin mutant that had lost its ability to produce pediocin), or phosphate-buffered saline (PBS) for 18 days. This study showed that L. lactis and P. acidilactici MM33A increased the concentrations of total LAB and anaerobes while P. acidilactici MM33 decreased the Enterobacteriaceae populations. A second in vivo study was done using VRE-colonized mice that received the same inocula as those in the previous study for 16 days. In L. lactis-fed mice, fecal VRE levels 1.73 and 2.50 log(10) CFU/g lower than those in the PBS group were observed at 1 and 3 days postinfection. In the P. acidilactici MM33-fed mice, no reduction was observed at 1 day postinfection but a reduction of 1.85 log(10) CFU/g was measured at 3 days postinfection. Levels of VRE in both groups of mice treated with bacteriocin-producing LAB were undetectable at 6 days postinfection. No significant difference in mice fed the pediocin-negative strain compared to the control group was observed. This is the first demonstration that human L. lactis and P. acidilactici nisin- and pediocin-producing strains can reduce VRE intestinal colonization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245231      PMCID: PMC2292579          DOI: 10.1128/AEM.02150-07

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  31 in total

1.  MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens.

Authors:  M Mota-Meira; G LaPointe; C Lacroix; M C Lavoie
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

Review 2.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Effects of Lactococcus lactis on composition of intestinal microbiota: role of nisin.

Authors:  Nete Bernbom; Tine Rask Licht; Carl-Henrik Brogren; Birthe Jelle; Anette H Johansen; Iker Badiola; Finn K Vogensen; Birgit Nørrung
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

4.  Bacteriocins as alternative agents for control of multiresistant staphylococcal strains.

Authors:  J S Nascimento; H Ceotto; S B Nascimento; M Giambiagi-Demarval; K R N Santos; M C F Bastos
Journal:  Lett Appl Microbiol       Date:  2006-03       Impact factor: 2.858

5.  Alteration of the canine small-intestinal lactic acid bacterium microbiota by feeding of potential probiotics.

Authors:  Titta J K Manninen; Minna L Rinkinen; Shea S Beasley; Per E J Saris
Journal:  Appl Environ Microbiol       Date:  2006-10       Impact factor: 4.792

6.  Partial characterization of bacteriocins produced by human Lactococcus lactis and Pediococccus acidilactici isolates.

Authors:  M Millette; C Dupont; D Archambault; M Lacroix
Journal:  J Appl Microbiol       Date:  2007-01       Impact factor: 3.772

7.  Surveillance for vancomycin-resistant enterococci: type, rates, costs, and implications.

Authors:  Brooke N Shadel; Laura A Puzniak; Kathleen N Gillespie; Steven J Lawrence; Marin Kollef; Linda M Mundy
Journal:  Infect Control Hosp Epidemiol       Date:  2006-09-21       Impact factor: 3.254

8.  Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial.

Authors:  Karen J Manley; Margaret B Fraenkel; Barrie C Mayall; David A Power
Journal:  Med J Aust       Date:  2007-05-07       Impact factor: 7.738

9.  Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118.

Authors:  Sinéad C Corr; Yin Li; Christian U Riedel; Paul W O'Toole; Colin Hill; Cormac G M Gahan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-24       Impact factor: 11.205

10.  Purification and identification of the pediocin produced by Pediococcus acidilactici MM33, a new human intestinal strain.

Authors:  M Millette; C Dupont; F Shareck; M T Ruiz; D Archambault; M Lacroix
Journal:  J Appl Microbiol       Date:  2007-10-09       Impact factor: 3.772

View more
  47 in total

Review 1.  Bacteriocin production: a probiotic trait?

Authors:  Alleson Dobson; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Appl Environ Microbiol       Date:  2011-10-28       Impact factor: 4.792

2.  Lactococcus lactis KA-FF 1-4 reduces vancomycin-resistant enterococci and impacts the human gut microbiome.

Authors:  Sa-Ngapong Plupjeen; Wireeya Chawjiraphan; Suvimol Charoensiddhi; Sunee Nitisinprasert; Massalin Nakphaichit
Journal:  3 Biotech       Date:  2020-06-08       Impact factor: 2.406

Review 3.  Bacteriocins - a viable alternative to antibiotics?

Authors:  Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Nat Rev Microbiol       Date:  2012-12-24       Impact factor: 60.633

Review 4.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

Review 5.  Overview of the Effect of Citrobacter rodentium Infection on Host Metabolism and the Microbiota.

Authors:  Eve G D Hopkins; Gad Frankel
Journal:  Methods Mol Biol       Date:  2021

Review 6.  Microbiome therapeutics - Advances and challenges.

Authors:  Mark Mimee; Robert J Citorik; Timothy K Lu
Journal:  Adv Drug Deliv Rev       Date:  2016-05-05       Impact factor: 15.470

7.  Enterococci and Their Interactions with the Intestinal Microbiome.

Authors:  Krista Dubin; Eric G Pamer
Journal:  Microbiol Spectr       Date:  2014-11

8.  Lack of Heterogeneity in Bacteriocin Production Across a Selection of Commercial Probiotic Products.

Authors:  J W Hegarty; C M Guinane; R P Ross; C Hill; P D Cotter
Journal:  Probiotics Antimicrob Proteins       Date:  2017-12       Impact factor: 4.609

Review 9.  The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens.

Authors:  Sohn Kim; April Covington; Eric G Pamer
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

10.  Like will to like: abundances of closely related species can predict susceptibility to intestinal colonization by pathogenic and commensal bacteria.

Authors:  Bärbel Stecher; Samuel Chaffron; Rina Käppeli; Siegfried Hapfelmeier; Susanne Freedrich; Thomas C Weber; Jorum Kirundi; Mrutyunjay Suar; Kathy D McCoy; Christian von Mering; Andrew J Macpherson; Wolf-Dietrich Hardt
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.